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Bisphosphonates (BPs) are a group of compounds derived from bisphosphonic acid and 
their salts, with a P-C-P structure which confers higher metabolic and chemical stability. 
They are an important class of drugs with therapeutic applications in the treatment of 
diseases of bone mineral metabolism such as osteoporosis and Paget's disease. These 
compounds have also shown activity in other areas, such as antitumor and antiparasitic 
activities.1 The use of these compounds in therapy is affected by their low oral bioavailability 
due to low lipophilicity and the presence of charges at physiological pH. The improvement 
of their pharmacokinetic properties can be obtained by the use of ester derivatives as 
prodrugs.2 
In this work, we present the synthesis and characterization of various phosphonic acids and 
esters derivatives of indazole (Figure 1). The biological activity of these compounds were 
evaluated including their toxicity, antioxidant and antimicrobial activities.3 Bisphosphonic 
acid derivatives showed broad spectra with high activity against Gram – and Gram + 
pathogenic and commensal bacteria. These compounds also present antioxidant activity by 
the β-carotene/linoleic acid method. 
 
 
 
Figure 1: Structure of studied phosphonates derived from indazole. 
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